Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Harmony Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$909,168

341 payments

Through program year 2025, Harmony Clinical Research Inc is reported as receiving $909,168 in research payments, across 341 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $54,222 9
2024 Research $110,511 14
2023 Research $251,802 45
2022 Research $125,424 83
2021 Research $131,837 120
2020 Research $63,480 38
2019 Research $171,892 32

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $352,343 30 payments
  2. Sanofi US Services Inc. $168,093 30 payments
  3. Biohaven Pharmaceuticals, Inc. $127,486 48 payments
  4. Esperion Therapeutics, Inc. $93,161 163 payments
  5. Janssen Research & Development, LLC $50,396 6 payments
  6. AbbVie, Inc. $35,609 16 payments
  7. Tolmar, Inc. $27,965 9 payments
  8. Vanda Pharmaceuticals Inc. $19,766 18 payments
  9. Genentech, Inc. $16,636 16 payments
  10. Lexicon Pharmaceuticals, Inc. $12,225 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T $233,486 10 payments
  2. A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $118,857 20 payments
  3. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $93,161 163 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $89,648 2 payments
  5. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $86,058 35 payments
  6. A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 $50,396 6 payments
  7. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $33,001 15 payments
  8. A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $25,448 1 payment
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea Alone or in Combination With Metformin in $24,652 13 payments
  10. A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months $24,139 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record